Analysis, commentary examine access to, unmet need for contraceptives

NewsGuard 100/100 Score

In an analysis published online in the Lancet, researchers from the National University of Singapore and the U.N. Population Division "estimated and projected indicators of contraceptive prevalence and unmet need for family planning from 1990 to 2015," according to the paper's abstract. Based on their data and methodology, the researchers note, "Worldwide, contraceptive prevalence increased from 54.8 percent (95 percent uncertainty interval 52.3-57.1) in 1990, to 63.3 percent (60.4-66.0) in 2010, and unmet need for family planning decreased from 15.4 percent (14.1-16.9) in 1990, to 12.3 percent (10.9-13.9) in 2010." However, "[t]he absolute number of married women who either use contraception or who have an unmet need for family planning is projected to grow from 900 million (876-922 million) in 2010 to 962 million (927-992 million) in 2015, and will increase in most developing countries," they state, concluding "that increased investment is necessary to meet demand for contraceptive methods and improve reproductive health worldwide" (Alkema et al., 3/12). An accompanying commentary states the study's "estimates support the call at the 2012 London Summit on Family Planning for a focused effort to bring contraception to people in countries where its use is still confined to a minority" (Cleland/Shah, 3/12).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
At stake in mifepristone case: Abortion, FDA’s authority, and return to 1873 obscenity law